Close Sidebar
Nordic Life Science
Now Reading
Russian yes to simeprevir
Search for content, post, videos
Search for content, post, videos
Advertisement

Russian yes to simeprevir

March 25, 2014
1742 Views

The Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, announces Medivir.

Russia will be the first country within EMEA to gain access to simeprevir. “The Russian approval is another important event for simeprevir and provides the hepatitis C patients in Russia with a new HCV treatment” said Maris Hartmanis CEO, Medivir.

Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.

Advertisement
Advertisement

Related Posts

genmab
May 24, 2016

Genmab has announced that the European Commission (EC) has granted a conditional marketing authorization for first-in-class CD38 antibody DARZALEX (daratumumab). The conditional approval is for the use of DARZALEX as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI)…

alzheimers
August 23, 2016

AstraZeneca and Eli Lilly and Company have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA’s Fast Track programme is designed to expedite the…

Alderley-Park
March 12, 2014

AstraZeneca is selling its Alderley Park site in Cheshire, UK, to Manchester Science Parks. Manchester Science Parks (MSP) is a Manchester-based public-private partnership and science park operator. Chris Oglesby, Chairman of MSP and Chief Executive of MSP majority shareholder, Bruntwood, commented in a statement: “We are delighted to have been entrusted with…

Upsalite-Photo-Simon-Ydhag
July 18, 2015

Astra Zeneca’s experimental lung cancer pill delayed the progression of the disease by more than a year, the company said at the European Lung Cancer Congress 2015 in Geneva, Switzerland, recently. The data came from the firm’s Phase II study on approximately 300 patients, which showed a 54 percent overall…